Nanotechnology in medical imaging: Probe design and applications

Arteriosclerosis, Thrombosis, and Vascular Biology

Volumn 29, Issue 7, 2009, Pages 992-1000

  Cormode, David P ^a   Skajaa, Torjus ^a,b   Fayad, Zahi A ^a   Mulder, Willem J M ^a  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^b AARHUS UNIVERSITY   (Denmark)

Author keywords

Drug delivery; Gene therapy; Magnetic resonance imaging; Molecular imaging; Nanotechnology

Indexed keywords

CONTRAST MEDIUM; GADOLINIUM; GREEN FLUORESCENT PROTEIN; IRON OXIDE; MACROGOL; NANOPARTICLE; RED FLUORESCENT PROTEIN; VITRONECTIN RECEPTOR; DIAGNOSTIC AGENT;

ANGIOGENESIS; CONTRAST ENHANCEMENT; DIAGNOSTIC IMAGING; DRUG DESIGN; MICROEMULSION; MOLECULAR IMAGING; MOLECULAR PROBE; NANOTECHNOLOGY; NUCLEAR MAGNETIC RESONANCE IMAGING; PARTICLE SIZE; PRIORITY JOURNAL; REVIEW; ANIMAL; ATHEROSCLEROSIS; CHEMISTRY; GENETIC PROCEDURES; HUMAN; METHODOLOGY; MOUSE; RABBIT; SYNTHESIS;

ANIMALS; ATHEROSCLEROSIS; BIOSENSING TECHNIQUES; CONTRAST MEDIA; DIAGNOSTIC IMAGING; HUMANS; MICE; NANOPARTICLES; RABBITS;

EID: 66149184908     PISSN: 10795642     EISSN: None     Source Type: Journal    
DOI: 10.1161/ATVBAHA.108.165506     Document Type: Review

References (91)

1. Corot C, Robert P, Idee J-M, Port M. Recent advances in iron oxide nanocrystal technology for medical imaging. Adv Drug Deliv Rev. 2006; 58:1471-1504.
2. Mulder WJM, Griffioen AW, Strijkers GJ, Cormode DP, Nicolay K, Fayad ZA. Magnetic and fluorescent nanoparticles for multimodality imaging. Nanomedicine. 2007;2:307-324.
3. Huang X, Jain PK, El-Sayed IH, El-Sayed M. Gold nanoparticles: interesting optical properties and recent applications in cancer diagnostics and therapy. Nanomedicine. 2007;2:681- 693.
4. Azzazy HME, Mansour MMH, Kazmierczak SC. From diagnostics to therapy: Prospects of quantum dots. Clin Biochem. 2007;40:917-927.
5. Wickline SA, Neubauer AM, Winter PM, Caruthers SD, Lanza GM. Molecular imaging and therapy of atherosclerosis with targeted nanoparticles. J Magn Reson Imaging. 2007;25:667- 680.
6. Medintz IL, Uyeda HT, Goldman ER, Mattoussi H. Quantum dot bioconjugates for imaging, labelling and sensing. Nat Mater. 2005;4: 435-446.
7. Nahrendorf M, Zhang H, Hembrador S, Panizzi P, Sosnovik DE, Aikawa E, Libby P, Swirski FK, Weissleder R. Nanoparticle PET-CT imaging of macrophages in inflammatory atherosclerosis. Circulation. 2008;117: 379-387.
8. Klibanov AL, Maruyama K, Torchilin VP, Huang L. Amphipatic polyethyleneglycols effectively prolong the circulation time of liposomes. FEBS Lett. 1990;268:235-238.
9. Allen TM, Hansen C, Martin F, Redemann C, Yau-Young A. Liposomes containing synthetic lipid derivatives of poly(ethylene glycol) show prolonged circulation half-lives in vivo. Biochim Biophys Acta. 1991;1066: 29-36.
10. Schmieder AH, Winter PM, Caruthers SD, Harris TD, Williams TA, Allen JS, Lacy EK, Zhang HY, Scott MJ, Hu G, Robertson JD, Wickline SA, Lanza GM. Molecular MR imaging of melanoma angiogenesis with alpha(nu)beta(3)-targeted paramagnetic nanoparticles. Magn Res Med. 2005;53:621- 627.
11. Winter PM, Neubauer AM, Caruthers SD, Harris TD, Robertson JD, Williams TA, Schmieder AH, Hu G, Allen JS, Lacy EK, Zhang HY, Wickline SA, Lanza GM Endothelial alpha (v) beta(3) integrin-targeted fumagillin nanoparticles inhibit angiogenesis in atherosclerosis. Arterioscler Thromb Vasc Biol. 2006;26:2103-2109.
12. Amirbekian V, Lipinski MJ, Briley-Saebo KC, Amirbekian S, Aguinaldo JG, Weinreb DB, Vucic E, Frias JC, Hyafil F, Mani V, Fisher EA, Fayad ZA. Detecting and assessing macrophages in vivo to evaluate atherosclerosis noninvasively using molecular MRI. Proc Natl Acad Sci U S A. 2007;104:961-966.
13. Durr NJ, Larson T, Smith DK, Korgel BA, Sokolov K, Ben-Yakar A. Two-photon luminescence imaging of cancer cells using molecularly targeted gold nanorods. Nano Lett. 2007;7:941-945.
14. Del Vecchio S, Zanneti A, Fonti R, Pace L, Salvatore M. Nuclear imaging in cancer theranostics. Quart J Nucl Med Mol Im. 2007;51:152-163.
15. Mulder WJM, Strijkers GJ, Briley-Saeboe KC, Frias JC, Aguinaldo JGS, Vucic E, Amirbekian V, Tang C, Chin PTK, Nicolay K, Fayad ZA. Molecular imaging of macrophages in atherosclerotic plaques using bimodal PEG-micelles. Magn Res Med. 2007;58:1164-1170.
16. Winter PM, Caruthers SD, Zhang H, Williams TA, Wickline SA, Lanza GM. Antiangiogenic synergism of integrin-targeted fumagillin nanoparticles and atorvastatin in atherosclerosis. J Am Coll Cardiol: Cardiovasc Im. 2008;1:624-634.
17. Winter PM, Cai K, Chen J, Adair CR, Kiefer GE, Athey PS, Gaffney PJ, Buff CE, Robertson JD, Caruthers SD, Wickline SA, Lanza GM. Targeted PARACEST nanoparticle contrast agent for the detection of fibrin. Magn Reson Med. 2006;56:1384-1388.
18. Cyrus T, Abendschein DR, Caruthers SD, Harris TD, Glattauer V, Werkmeister JA, Ramshaw JAM, Wickline SA, Lanza GM.MRthree-dimensional molecular imaging of intramural biomarkers with targeted nanoparticles. J Cardiovasc Magn Reson. 2006;8:1-7.
19. Ahrens ET, Flores R, Xu H, Morel PA. In vivo imaging platform for tracking immunotherapeutic cells. Nat Biotech. 2005;23:983-987.
20. Bulte J. Hot spot MRI emerges from the background. Nat Biotech. 2005;23:945-946.
21. Medarova Z, Pham W, Farrar C, Petkova V, Moore A. In vivo imaging of siRNA delivery and silencing in tumors. Nat Med. 2007;13:372-377.
22. Mulder WJM, Douma K, Koning GA, van Zandvoort MA, Lutgens E, Daemen MJ, Nicolay K, Strijkers GJ. Liposome-enhanced MRI of neointimal lesions in the apoE-KO mouse. Magn Res Med. 2006;55: 1170-1174.
23. Lanza GM, Winter PM, Caruthers SD, Hughes MS, Cyrus T, Marsh JN, Neubauer AM, Partlow KC, Wickline SA. Nanomedicine opportunities for cardiovascular disease with perfluorocarbon nanoparticles. Nanomedicine. 2006;1:321-329.
24. Frias JC, Williams KJ, Fisher EA, Fayad ZA. Recombinant HDL-like nanoparticles: a specific contrast agent for MRI of atherosclerotic plaques. J Am Chem Soc. 2004;126:16316-16317.
25. Anderson EA, Isaacman S, Peadbody DS, Wang EY, Canary JW, Kirshenbaum K. Viral nanoparticles donning a paramagnetic coat: conjugation of MRI contrast agents to the MS2 capsid. Nano Lett. 2006;6:1160-1164.
26. Sitharaman B, Kissell KR, Hartman KB, Tran LA, Baikalov A, Rusakova I, Sun Y, Khant HA, Ludtke SJ, Chiu W, Laus S, Toth W, Helm L, Merbach AE Superparamagnetic gadonanotubes are high-performance MRI contrast agents. Chem Commun. 2005;3915-3917.
27. van Tilborg GAF, Mulder WJM, Deckers N, Storm G, Reutelingsperger CPM, Strijkers GJ, Nicolay K. Annexin A5-functionalized bimodal lipid-based contrast agents for the detection of apoptosis. Bioconjate Chem. 2006;17:741-749.
28. Lipinski MJ, Briley-Saebo KC, Mani V, Fayad ZA. "Positive contrast" inversion-recovery with oxide nanoparticles-resonant water suppression magnetic resonance imaging: a change for the better? J Am Coll Cardiol. 2008;52:492- 494.
29. Briley-Saebo KC, Mulder WJM, Mani V, Hyafil F, Amirbekian V, Aguinaldo JGS, Fisher EA, Fayad ZA. Magnetic resonance imaging of vulnerable atherosclerotic plaques: Current imaging strategies and molecular imaging probes. J Magn Reson Imaging. 2007;26:460-479.
30. Walczak P, Zhang J, Gilad AA, Kedziorek DA, Ruiz-Cabello J, Young RG, Pittenger MF, Van Zijl PCM, Huang J, Bulte JWM. Dual-modality monitoring of targeted intraarterial delivery of mesenchymal stem cells after transient ischemia. Stroke. 2008;39:1569-1574.
31. Leatherdale CA, Woo W-K, Mikulec FV, Bawendi MG. On the absorption cross section of CdSe nanocrystal quantum dots. J Phys Chem B. 2002;116: 7619-7622.
32. Bruchez M, Jr., Moronne M, Gin P, Weiss S, Alivisatos AP. Semiconductor Nanocrystals as Fluorescent Biological Labels. Science. 1998;281: 2013-2016.
33. Sukhanova A, Devy M, Venteo L, Kaplan H, Artemyev M, Oleinikov V, Klinov D, Pluot M, Cohen JHM, Nabiev I. Biocompatible fluorescent nanocrystals for immunolabeling of membrane proteins and cells. Anal Biochem. 2004;324:60-67.
34. Sosnovik D, Weissleder R. Magnetic resonance and fluorescence based molecular imaging technologies. Progress Drug Res. 2005;62:86-114.
35. Hyafil F, Cornily JC, Feig JE, Gordon R, Vucic E, Amirbekian V, Fisher EA, Fuster V, Feldman LJ, Fayad ZA. Noninvasive detection of macrophages using a nanoparticulate contrast agent for computed tomography. Nat Med. 2007;13:636-641.
36. Rabin O, Perez JM, Grimm J, Wojtkiewicz G, Weissleder R. An X-ray computed tomography imaging agent based on long-circulating bismuth sulphide nanoparticles. Nat Mater. 2006;5:118-122.
37. Hainfeld JF, Slatkin DN, Focella TM, Smilowitz HM. Gold nanoparticles: a new X-ray contrast agent. Brit J Radiol. 2006;79:248-253.
38. Mukundan S, Ghaghada KB, Badea CT, Kao C-Y, Hedlund LW, Provanzale JM, Johnson GA, Chen E, Bellamkonda RV, Annapragada A. A liposomal nanoscale contrast agent for preclinical CT in mice. AJR. 2006;186:300-307.
39. Kim D, Park S, Lee JH, Jeong YY, Jon S. Antibiofouling polymer-coated gold nanoparticles as a contrast agent for in vivo x-ray computed tomography imaging. J Am Chem Soc. 2007;129:7661-7665.
40. Lumbroso P, Dick CE. X-ray attenuation properties of radiographic contrast media. Med Phys. 1987;14:752-758.
41. Weissleder R, Mahmood U. Molecular Imaging. Radiology. 2001;219: 316-333.
42. Villanueva FS, Jankowski RJ, Klibanov S, Pina ML, Alber SM, Watkins SC, Brandenburger GH, Wagner WR. Microbubbles targeted to intercellular adhesion molecule-1 bind to activated coronary artery endothelial cells. Circulation. 1998;98:1-5.
43. Klibanov AL. Microbubble contrast agents targeted ultrasound imaging and ultrasound-assisted drug-delivery applications. Invest Radiol. 2006; 41:354-362.
44. Huang SL, Hamilton AJ, Pozharski E, Nagaraj A, Klegerman ME, McPherson DD, MacDonald RC. Physical correlates of the ultrasonic reflectivity of lipid dispersions suitable as diagnostic contrast agents. Ultrasound Med Biol. 2002;28:339-348.
45. Lanza GM, Wallace KD, Scott MJ, Cacheris WP, Abendschein DR, Christy DH, Sharkey AM, Miller JG, Gaffney PJ, Wickline SA. A novel site-targeted ultrasonic contrast agent with broad biomedical application. Circulation. 1996;94:3334-3340.
46. Schiffelers RM, Banciu M, Metselaar JM, Storm G. Therapeutic application of long circulation liposomal glucocorticoids in auto-immune diseases and cancer. J Liposome Res. 2006;16:185-194.
47. Berry CC, Wells S, Charles S, Curtis ASG. Dextran and albumin derivatised iron oxide nanoparticles: influence on fibroblasts in vitro. Biomaterials. 2003;24:4551- 4557.
48. Liu HL, Ko SP, Wu JH, Jung MH, Min JH, Lee JH, An BH, Kim YK. One-pot polyol synthesis of monosize PVP-coated sub-5nm Fe3O4 nanoparticles for biomedical applications. J Magnetism Magnetic Mater. 2007;310:E815-E817.
49. Zhang Y, Kohler N, Zhang M. Surface modification of superparamagnetic magnetite nanoparticles and their intracellular uptake. Biomaterials. 2002;23:1553-1561.
50. Selvan ST, Tan TT, Ying JY. Robust, non-cytotoxic, silica-coated CdSe quantum dots with efficient photoluminescence. Adv Mater. 2005;17: 1620-1625.
51. Otsuka H, Nagasaki Y, Kataoka K. PEGylated nanoparticles for biological and pharmaceutical applications. Adv Drug Deliv. 2003;55: 403-419.
52. Vallet-Regi M, Balas F, Arcos D. Mesoporous materials for drug delivery. Angew Chem Int Ed. 2007;46:7548-7558.
53. Chowdhury EH, Akaike T. Bio-functional inorganic materials: An attractive branch of gene-based nano-medicine delivery for 21st century. Curr Gene Ther. 2005;5:669-676.
54. Slowing II, Trewyn BG, Lin VSY. Mesoporous silica nanoparticles for intracellular delivery of membrane-impermeable proteins. J Am Chem Soc. 2007;129:8845- 8849.
55. van Schooneveld MM, Vucic E, Koole R, Zhou Y, Stocks J, Cormode DP, Tang CY, Gordon R, Nicolay K, Meijerink A, Fayad ZA, Mulder WJM. Improved biocompatibility and pharmacokinetics of silica nanoparticles by means of a lipid coating: a multimodality investigation. Nano Lett. 2008;8:2517-2525.
56. Cormode DP, Mulder WJM, Fisher EA, Fayad ZA. Modified lipoproteins as contrast agents for molecular imaging. Future Lipidol. 2007;2: 587-590.
57. Huang X, Bronstein LM, Retrum J, Dufort C, Tsvetkova I, Aniagyei S, Stein B, Stucky G, McKenna B, Rennes N, Baxter D, Kao CC, Dragnea B. Self-assembled virus-like particles with magnetic cores. Nano Lett. 2007;7:2407-2416.
58. Sun J, DuFort C, Daniel M-C, Murali A, Chen C, Gopinath K, Stein B, De M, Rotello VM, Holzenburg A, Kao CC, Dragnea B. Core-controlled polymorphism in virus-like particles. Proc Natl Acad Sci U S A. 2007; 104:1354-1359.
59. Cormode DP, Skajaa T, van Schooneveld MM, Koole R, Jarzyna P, Lobatto ME, Calcagno C, Barazza A, Gordon RE, Zanzonico P, Fisher EA, Fayad ZA, Mulder WJM. Nanocrystal core high-density lipoproteins: A multimodal molecular imaging contrast agent platform. Nano Lett. 2008;8:3715-3723.
60. Sanz J, Fayad ZA. Imaging of atherosclerotic cardiovascular disease. Nature. 2008;451:953-957.
61. Kwon GS, Kataoka K. Block copolymer micelles as long-circulating drug vehicles. Adv Drug Deliv Rev. 1995;16:295-309.
62. Ruehm SG, Corot C, Vogt P, Kolb S, Debatin JF. Magnetic resonance imaging of atherosclerotic plaque with ultrasmall superparamagnetic particles of iron oxide in hyperlipidemic rabbits. Circulation. 2001;103: 415-422.
63. Kang HW, Weissleder R, Bogdanov A. Targeting of MPEG-protected polyamino acid carrier to human E-selectin in vitro. Amino Acids. 2002; 23:301-308.
64. Schellenberger EA, Sosnovik D, Weissleder R, Josephson L. Magneto/ optical annexin V, a multimodal protein. Bioconjugate Chem. 2004;15: 1062-1067.
65. Nahrendorf M, Jaffer FA, Kelly KA, Sosnovik DE, Aikawa E, Libby P, Weissleder R. Noninvasive vascular cell adhesion molecule-1 imaging identifies inflammatory activation of cells in atherosclerosis. Circulation. 2006;114:1504-1511.
66. Javier DJ, Nitin N, Levy M, Ellington A, Richards-Kortum R. Aptamertargeted gold nanoparticles as molecular-specific contrast agents for reflectance imaging. Bioconjugate Chem. 2008;19:1309-1312.
67. Villanueva FS, Lu EX, Bowry S, Kilic S, Tom E, Wang JJ, Gretton J, Pacella JJ, Wagner WR. Myocardial ischemic memory imaging with molecular echocardiography. Circulation. 2007;115:345-352.
68. Zheng G, Chen J, Li H, Glickson JD. Rerouting lipoprotein nanoparticles to selected alternate receptors for the targeted delivery of cancer diagnostic and therapeutic agents. Proc Natl Acad Sci U S A. 2005;102: 17757-17762.
69. Frangioni JV. New technologies for human cancer imaging. J Clin Oncol. 2008;26:4012- 4021.
70. Weissleder R, Kelly K, Sun EY, Shtatland T, Josephson L. Cell-specific targeting of nanoparticles by multivalent attachment of small nanoparticles. Nat Biotech. 2005;23:1418-1423.
71. Serda RE, Adolphi NL, Bisoffi M, Sillerud LO. Targeting and cellular trafficking of magnetic nanoparticles for prostate cancer imaging. Mol Imaging. 2007;6:277-288.
72. Paganelli G, Chinol M, Maggiolo M, Sidoli A, Corti A, Baroni S, Siccardi AG. The three-step pretargeting approach reduces the human anti-mouse antibody response in patients submitted to radioimmunoscintigraphy and radioimmunotherapy. Eur J Nucl Med. 1997;24:350-351.
73. Torchilin VP. Recent advances with liposomes as pharmaceutical carriers. Nat Rev Drug Discov. 2005;4:145-160.
74. Gupta AK, Gupta M. Synthesis and surface engineering of iron oxide nanoparticles for biomedical applications. Biomaterials. 2005;26: 3995-4021.
75. Hostetler MJ, Wingate JE, Zhong CJ, Harris JE, Vachet RW, Clark MR, Londono JD, Green SJ, Stokes JJ, Wignall GD, Glish GL, Porter MD, Evans ND, Murray RW. Alkanethiolate gold cluster molecules with core diameters from 1.5 to 5.2 nm: core and monolayer properties as a function of core size. Langmuir. 1998;14:17-30.
76. van Helden AK, Jansen JW, Vrij A. Preparation and characterization of spherical monodisperse silica dispersions in nonaqueous solvents. J Colloid Interface Sci. 1980;78:354-368.
77. Murray CB, Norris DJ, Bawendi MG. Synthesis and characterization of nearly monodisperse CdE (E=S, Se, Te) semiconductor nanocrystallites. J Am Chem Soc. 1993;115:8706-8715.
78. Choi HS, Liu W, Misra P, Tanaka E, Zimmer JP, Ipe BI, Bawendi MG, Frangioni JV. Renal clearance of quantum dots. Nat Biotech. 2007;25: 1165-1170.
79. Michalet X, Pinaud FF, Bentolila LA, Tsay JM, Doose S, Li JJ, Sundaresan G, Wu AM, Gambhir SS, Weiss S. Quantum dots for live cells, in vivo imaging, and diagnostics. Science. 2005;307:538-544.
80. McAteer MA, Sibson NR, von zur Muhlen C, Schneider JE, Lowe AS, Warrick N, Channon KM, Anthony DC, Choudhury RP. In vivo magnetic resonance imaging of acute brain inflammation using microparticles of iron oxide. Nat Med. 2007;13:1253-1258.
81. Gleich B, Weizenecker J. Tomographic imaging using the nonlinear response of magnetic particles. Nat Biotech. 2005;435:1214-1217.
82. Gaumet M, Vargas A, Gurny R, Delie F. Nanoparticles for drug delivery: the need for precision in reporting particle size parameters. Eur J Pharm Biopharm. 2008;69:1-9.
83. Brust M, Walker M, Bethell D, Schiffrin DJ, Whyman R Synthesis of thiol-derivatised gold nanoparticles in a two-phase liquid-liquid system. Chem Commun. 1994;801- 802.
84. Kim BS, Qiu JM, Wang JP, Taton TA. Magnetomicelles: composite nanostructures from magnetic nanoparticles and cross-linked amphiphilic block copolymers. Nano Lett. 2005;5:1987-1991.
85. Yu WW, Chang E, Falkner JC, Zhang J, Al-Somali AM, Sayes CM, Johns J, Drezek R, Colvin VL. Forming biocompatible and nonaggregated nanocrystals in water using amphiphilic polymers. J Am Chem Soc. 2007;129:2871-2879.
86. McCarthy JR, Kelly KA, Sun EY, Weissleder R. Targeted delivery of multifunctional magnetic nanoparticles. Nanomedicine. 2007;2:153-167.
87. http://www.fda.gov/nanotechnology/.
88. Davies JC Nanotechnology Oversight: An Agenda for the New Administration. Woodrow Wilson International Center for Scholars, Project on Emerging Nanotechnologies. 2008;PEN 13.
89. http://nanoehsalliance.org/.
90. Shaw SY, Westly EC, Pittet MJ, Subramanian A, Schreiber SL, Weissleder R. Perturbational profiling of nanomaterial biologic activity. Proc Natl Acad Sci U S A. 2008;105:7387-7392.
91. Mancini MC, Kairdolf BA, Smith AM, Nie S. Oxidative quenching and degradation of polymer-encapsulated quantum dots: new insights into the long-term fate and toxicity of nanocrystals in vivo. J Am Chem Soc. 2008;130:10836-10837.